1. Home
  2. SBI vs CHRS Comparison

SBI vs CHRS Comparison

Compare SBI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBI
  • CHRS
  • Stock Information
  • Founded
  • SBI 1992
  • CHRS 2010
  • Country
  • SBI United States
  • CHRS United States
  • Employees
  • SBI N/A
  • CHRS N/A
  • Industry
  • SBI Finance/Investors Services
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SBI Finance
  • CHRS Health Care
  • Exchange
  • SBI Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • SBI 104.9M
  • CHRS 84.2M
  • IPO Year
  • SBI N/A
  • CHRS 2014
  • Fundamental
  • Price
  • SBI $7.62
  • CHRS $0.90
  • Analyst Decision
  • SBI
  • CHRS Buy
  • Analyst Count
  • SBI 0
  • CHRS 3
  • Target Price
  • SBI N/A
  • CHRS $4.68
  • AVG Volume (30 Days)
  • SBI 39.5K
  • CHRS 1.3M
  • Earning Date
  • SBI 01-01-0001
  • CHRS 08-07-2025
  • Dividend Yield
  • SBI 4.52%
  • CHRS N/A
  • EPS Growth
  • SBI N/A
  • CHRS N/A
  • EPS
  • SBI N/A
  • CHRS N/A
  • Revenue
  • SBI N/A
  • CHRS $272,251,000.00
  • Revenue This Year
  • SBI N/A
  • CHRS N/A
  • Revenue Next Year
  • SBI N/A
  • CHRS $99.43
  • P/E Ratio
  • SBI N/A
  • CHRS $2.07
  • Revenue Growth
  • SBI N/A
  • CHRS 19.87
  • 52 Week Low
  • SBI $6.96
  • CHRS $0.66
  • 52 Week High
  • SBI $8.00
  • CHRS $2.43
  • Technical
  • Relative Strength Index (RSI)
  • SBI 68.96
  • CHRS 59.04
  • Support Level
  • SBI $7.40
  • CHRS $0.73
  • Resistance Level
  • SBI $7.52
  • CHRS $0.82
  • Average True Range (ATR)
  • SBI 0.05
  • CHRS 0.04
  • MACD
  • SBI 0.02
  • CHRS 0.02
  • Stochastic Oscillator
  • SBI 100.00
  • CHRS 88.02

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: